The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Spinal Muscular Atrophy (SMA) Therapeutic Market Research Report 2025
Synopsis
Spinal muscular atrophy treatment market growth is driven by a significant increase in the number of product launches despite the relative rarity of the disorder and high costs associated with the approved drugs. The treatment of spinal muscular atrophy through the gene therapy drug called Zolgensma
The global Spinal Muscular Atrophy (SMA) Therapeutic market was valued at US$ 3845 million in 2023 and is anticipated to reach US$ 12460 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Therapeutic.
Report Scope
The Spinal Muscular Atrophy (SMA) Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy (SMA) Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Roche
Astellas Pharma
Genzyme Corporation
Segment by Type
Nusinersen
Onasemnogen Abeparvovec
Segment by Application
Type 1 SMA
Type 2 SMA
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Spinal muscular atrophy treatment market growth is driven by a significant increase in the number of product launches despite the relative rarity of the disorder and high costs associated with the approved drugs. The treatment of spinal muscular atrophy through the gene therapy drug called Zolgensma
The global Spinal Muscular Atrophy (SMA) Therapeutic market was valued at US$ 3845 million in 2023 and is anticipated to reach US$ 12460 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Therapeutic.
Report Scope
The Spinal Muscular Atrophy (SMA) Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal Muscular Atrophy (SMA) Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal Muscular Atrophy (SMA) Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Novartis
Roche
Astellas Pharma
Genzyme Corporation
Segment by Type
Nusinersen
Onasemnogen Abeparvovec
Segment by Application
Type 1 SMA
Type 2 SMA
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Nusinersen
1.2.3 Onasemnogen Abeparvovec
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Type 1 SMA
1.3.3 Type 2 SMA
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Perspective (2019-2030)
2.2 Spinal Muscular Atrophy (SMA) Therapeutic Growth Trends by Region
2.2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Spinal Muscular Atrophy (SMA) Therapeutic Market Dynamics
2.3.1 Spinal Muscular Atrophy (SMA) Therapeutic Industry Trends
2.3.2 Spinal Muscular Atrophy (SMA) Therapeutic Market Drivers
2.3.3 Spinal Muscular Atrophy (SMA) Therapeutic Market Challenges
2.3.4 Spinal Muscular Atrophy (SMA) Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Therapeutic Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Therapeutic Revenue
3.4 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Therapeutic Revenue in 2023
3.5 Spinal Muscular Atrophy (SMA) Therapeutic Key Players Head office and Area Served
3.6 Key Players Spinal Muscular Atrophy (SMA) Therapeutic Product Solution and Service
3.7 Date of Enter into Spinal Muscular Atrophy (SMA) Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal Muscular Atrophy (SMA) Therapeutic Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Type (2025-2030)
5 Spinal Muscular Atrophy (SMA) Therapeutic Breakdown Data by Application
5.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2019-2030)
6.2 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024)
6.4 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2019-2030)
7.2 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024)
7.4 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2019-2030)
9.2 Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Introduction
11.1.4 Biogen Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Introduction
11.2.4 Novartis Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Spinal Muscular Atrophy (SMA) Therapeutic Introduction
11.3.4 Roche Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Detail
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Introduction
11.4.4 Astellas Pharma Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
11.4.5 Astellas Pharma Recent Development
11.5 Genzyme Corporation
11.5.1 Genzyme Corporation Company Detail
11.5.2 Genzyme Corporation Business Overview
11.5.3 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Introduction
11.5.4 Genzyme Corporation Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
11.5.5 Genzyme Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Nusinersen
Table 3. Key Players of Onasemnogen Abeparvovec
Table 4. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Region (2019-2024)
Table 8. Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Region (2025-2030)
Table 10. Spinal Muscular Atrophy (SMA) Therapeutic Market Trends
Table 11. Spinal Muscular Atrophy (SMA) Therapeutic Market Drivers
Table 12. Spinal Muscular Atrophy (SMA) Therapeutic Market Challenges
Table 13. Spinal Muscular Atrophy (SMA) Therapeutic Market Restraints
Table 14. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Players (2019-2024)
Table 16. Global Top Spinal Muscular Atrophy (SMA) Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Therapeutic as of 2023)
Table 17. Ranking of Global Top Spinal Muscular Atrophy (SMA) Therapeutic Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Therapeutic Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Spinal Muscular Atrophy (SMA) Therapeutic Product Solution and Service
Table 21. Date of Enter into Spinal Muscular Atrophy (SMA) Therapeutic Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type (2019-2024)
Table 25. Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Type (2025-2030)
Table 27. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application (2019-2024)
Table 29. Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Application (2025-2030)
Table 31. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Country (2025-2030) & (US$ Million)
Table 46. Biogen Company Detail
Table 47. Biogen Business Overview
Table 48. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product
Table 49. Biogen Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024) & (US$ Million)
Table 50. Biogen Recent Development
Table 51. Novartis Company Detail
Table 52. Novartis Business Overview
Table 53. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product
Table 54. Novartis Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024) & (US$ Million)
Table 55. Novartis Recent Development
Table 56. Roche Company Detail
Table 57. Roche Business Overview
Table 58. Roche Spinal Muscular Atrophy (SMA) Therapeutic Product
Table 59. Roche Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024) & (US$ Million)
Table 60. Roche Recent Development
Table 61. Astellas Pharma Company Detail
Table 62. Astellas Pharma Business Overview
Table 63. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product
Table 64. Astellas Pharma Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024) & (US$ Million)
Table 65. Astellas Pharma Recent Development
Table 66. Genzyme Corporation Company Detail
Table 67. Genzyme Corporation Business Overview
Table 68. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product
Table 69. Genzyme Corporation Revenue in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024) & (US$ Million)
Table 70. Genzyme Corporation Recent Development
Table 71. Research Programs/Design for This Report
Table 72. Key Data Information from Secondary Sources
Table 73. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type: 2023 VS 2030
Figure 3. Nusinersen Features
Figure 4. Onasemnogen Abeparvovec Features
Figure 5. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2023 VS 2030
Figure 7. Type 1 SMA Case Studies
Figure 8. Type 2 SMA Case Studies
Figure 9. Other Case Studies
Figure 10. Spinal Muscular Atrophy (SMA) Therapeutic Report Years Considered
Figure 11. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Region: 2023 VS 2030
Figure 14. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Players in 2023
Figure 15. Global Top Spinal Muscular Atrophy (SMA) Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy (SMA) Therapeutic as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Therapeutic Revenue in 2023
Figure 17. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Country (2019-2030)
Figure 19. United States Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Country (2019-2030)
Figure 23. Germany Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Region (2019-2030)
Figure 31. China Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Country (2019-2030)
Figure 39. Mexico Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Country (2019-2030)
Figure 43. Turkey Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Biogen Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
Figure 46. Novartis Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
Figure 47. Roche Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
Figure 48. Astellas Pharma Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
Figure 49. Genzyme Corporation Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Therapeutic Business (2019-2024)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
